SCHEMBL8368489

SCHEMBL8368489

N#C[C]1CNCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19437253 0.75
SCHEMBL9380203 0.67
SCHEMBL21800420 0.64 PNMT (0.44)
SCHEMBL31111348 0.63 PNMT (0.43)
SCHEMBL7793899 0.62
SCHEMBL3144398 0.62
SCHEMBL371880 0.62
SCHEMBL156559 0.62
SCHEMBL667084 0.62
SCHEMBL16320462 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8877720-B2 Epirubicin derivatives TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2014-11-04 US claimed
US-20130131001-A1 Epirubicin Derivatives Tianjin Michele Sci-Tech Development Co., (CN) 2013-05-23 US claimed
EP-3592730-B1 PRODRUGS OF SULFASALAZINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE DISEASE TRULY TRANSLATIONAL SWEDEN AB (SE) 2021-08-04 EP disclosed
US-10703723-B2 Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease TRULY TRANSLATIONAL SWEDEN AB (SE) 2020-07-07 US disclosed
WO-2018162625-A1 PRODRUGS OF SULFASALAZINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE DISEASE TRULY TRANSLATIONAL SWEDEN AB (SE) 2018-09-13 WO disclosed
US-9040516-B2 Uracil derivative and use thereof for medical purposes SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2015-05-26 US disclosed
US-8877720-B2 Epirubicin derivatives TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2014-11-04 US disclosed
US-20140179670-A1 URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-06-26 US disclosed
EP-2740728-A1 URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES Dainippon Sumitomo Pharma Co., Ltd. (JP) 2014-06-11 EP disclosed
US-20130131001-A1 Epirubicin Derivatives Tianjin Michele Sci-Tech Development Co., (CN) 2013-05-23 US disclosed
EP-0888372-A1 OLIGONUCLEOTIDE-ANTHRACYCLINE AND OLIGONUCLEOTIDE-ANTHRACYCLINONE CONJUGATES CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 1999-01-07 EP disclosed
WO-1997011370-A1 RECOMBINANT PROTEINS HAVING MULTIPLE DISULFIDE BONDS AND THIOL-SUBSTITUTED CONJUGATES THEREOF IMMUNOMEDICS, INC. (US) 1997-03-27 WO disclosed
EP-0274174-B1 LIPOSOME/ANTHRAQUINONE DRUG COMPOSITION AND METHOD YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1992-11-04 EP disclosed
US-5043166-A Antitumor agents; side effect reduction HADASIT MEDICAL RESEARCH, INC. (IL) 1991-08-27 US disclosed
US-4898735-A Liposome/doxorubicin composition and method YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1990-02-06 US disclosed
US-4797285-A ANTIBIOTICS, FERRIOXAMINE YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1989-01-10 US disclosed
EP-0274174-A1 Liposome/anthraquinone drug composition and method YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1988-07-13 EP disclosed
US-4585859-A ANTITUMOR AGENTS SRI INTERNATIONAL (US) 1986-04-29 US disclosed
EP-0128670-A1 4-Demethoxy-3'-deamino-3'(4-morpholinyl) derivatives of anthracycline anticancer antibiotics ADRIA LABORATORIES, INC. (US) 1984-12-19 EP disclosed
US-4464529-A ANTITUMOR AGENTS SRI INTERNATIONAL (US) 1984-08-07 US disclosed